XBiotech USA, Inc.

XBiotech USA, Inc. is a pioneering global biosciences company specializing in the discovery, development, and commercialization of therapeutic antibodies using its True Human™ proprietary technology. Unlike traditional antibody therapies, XBiotech’s True Human™ antibodies are derived from individuals with natural immunity to certain diseases, making them 100 percent human. The company's diverse pipeline of True Human™ antibodies is aimed at oncology, inflammatory conditions, and infectious diseases, boasting the potential to enhance safety, efficacy, and tolerability. Founded in 2005, XBiotech is at the forefront of the Biotechnology and Health Care sectors with its unique approach. Although specific headquarters and recent investments are not disclosed, XBiotech's innovative approach to antibody therapies positions it as a compelling player in the biotech landscape, appealing to potential venture capital interests.